Dr. Ferzaan N Engineer
Cytecare Hospitals
Dr. Ferzaan Engineer is Co-founder and Chairman of Cytecare Hospitals. He is also the Co-founder and Joint Chairman of Medwell Ventures, which offers home healthcare services under the Nightingales brand. Ferzaan serves on the Board of Directors of Sun Pharma Advanced Research Company Ltd (SPARC) and Cytespace Research Pvt Ltd. Ferzaan helped launch the international CRO industry in India and served as Chairman and CEO of Quintiles India from 1997 to 2010. He was also a member of the Quintiles Asia-Pacific Management Board. He has also served on the Board of Cenduit LLC and on the Advisory Boards of Chiratae Ventures, Cellworks (USA) and Image Core Lab. A graduate of the LM College of Pharmacy in Ahmedabad, Ferzaan completed his PhD in Pharmaceutical Sciences from the University of South Carolina, USA. He attended executive management programs at INSEAD (France), IIMA (India) and the Kenan-Flagler Business School (USA). Ferzaan has previously worked as Assistant Professor of Pharmaceutical Sciences in the United States, followed by an industry position as Vice President of Research for Core Healthcare. He has been a member of professional bodies such as AAPS and AACP. He received the AACP New Investigator’s Award in 1990 and received research grants from the National Institutes of Health (NIH), USA. He has published papers in leading international journals and lectured at several conferences and at management schools such as IIMA and the Judge Business School at the University of Cambridge. He has served on the Advisory Board of the Indian Society for Clinical Research (ISCR) and has been a member of the CII National Committee on Drugs and Pharmaceuticals and the FICCI Pharmaceuticals and Biotechnology Committee. Ferzaan lives in Bangalore with his two children, Anaya (21) and Varun (27). He enjoys travel, jazz and art.
Cytecare Hospitals
Dr. Ferzaan Engineer is Co-founder and Chairman of Cytecare Hospitals. He is also the Co-founder and Joint Chairman of Medwell Ventures, which offers home healthcare services under the Nightingales brand. Ferzaan serves on the Board of Directors of Sun Pharma Advanced Research Company Ltd (SPARC) and Cytespace Research Pvt Ltd. Ferzaan helped launch the international CRO industry in India and served as Chairman and CEO of Quintiles India from 1997 to 2010. He was also a member of the Quintiles Asia-Pacific Management Board. He has also served on the Board of Cenduit LLC and on the Advisory Boards of Chiratae Ventures, Cellworks (USA) and Image Core Lab. A graduate of the LM College of Pharmacy in Ahmedabad, Ferzaan completed his PhD in Pharmaceutical Sciences from the University of South Carolina, USA. He attended executive management programs at INSEAD (France), IIMA (India) and the Kenan-Flagler Business School (USA). Ferzaan has previously worked as Assistant Professor of Pharmaceutical Sciences in the United States, followed by an industry position as Vice President of Research for Core Healthcare. He has been a member of professional bodies such as AAPS and AACP. He received the AACP New Investigator’s Award in 1990 and received research grants from the National Institutes of Health (NIH), USA. He has published papers in leading international journals and lectured at several conferences and at management schools such as IIMA and the Judge Business School at the University of Cambridge. He has served on the Advisory Board of the Indian Society for Clinical Research (ISCR) and has been a member of the CII National Committee on Drugs and Pharmaceuticals and the FICCI Pharmaceuticals and Biotechnology Committee. Ferzaan lives in Bangalore with his two children, Anaya (21) and Varun (27). He enjoys travel, jazz and art.
Dr Noushin Brealey
GSK
Noushin is the Medical Director at GSK’s Clinical Pharmacology Unit in Cambridge. A unit specialising in First-Time-in-Human and experimental medicine studies, she has transformed its output whilst making quality and safety core to its operation. Having trained in London and qualifying as a GP, she has spent over 20 years in pharmaceutical research. Her experience ranges across the development pathway from pre-candidate selection, early clinical pharmacology to full development, as well as five years spent in medicines regulation at the MHRA. Recent notable achievements include the clinical development and global submissions for TRELEGY (COPD) and labelling update to remove the boxed warning from inhaled corticosteroid (ICS) / long-acting beta2 agonist (LABA) combination medicines. Noushin is passionate about adopting novel approaches and ways of working to reduce risk and improve the efficiency in pharmaceutical research.
GSK
Noushin is the Medical Director at GSK’s Clinical Pharmacology Unit in Cambridge. A unit specialising in First-Time-in-Human and experimental medicine studies, she has transformed its output whilst making quality and safety core to its operation. Having trained in London and qualifying as a GP, she has spent over 20 years in pharmaceutical research. Her experience ranges across the development pathway from pre-candidate selection, early clinical pharmacology to full development, as well as five years spent in medicines regulation at the MHRA. Recent notable achievements include the clinical development and global submissions for TRELEGY (COPD) and labelling update to remove the boxed warning from inhaled corticosteroid (ICS) / long-acting beta2 agonist (LABA) combination medicines. Noushin is passionate about adopting novel approaches and ways of working to reduce risk and improve the efficiency in pharmaceutical research.
Dr. Al Palaniappan
GSK
29 year career in clinical research spanning early and late phase development programmes. Operating in both the pharmaceutical and CRO environments. For the past 17 years, Al has held senior leadership positions at GSK in central R&D, Business Operations, Study Operations and 5 years at R&D China. He is currently the Chief Operating Officer at GSK’s Clinical Pharmacology Unit in Cambridge UK, a 24 bedded unit specialising in First-Time-in-Human and experimental medicine study conduct.
GSK
29 year career in clinical research spanning early and late phase development programmes. Operating in both the pharmaceutical and CRO environments. For the past 17 years, Al has held senior leadership positions at GSK in central R&D, Business Operations, Study Operations and 5 years at R&D China. He is currently the Chief Operating Officer at GSK’s Clinical Pharmacology Unit in Cambridge UK, a 24 bedded unit specialising in First-Time-in-Human and experimental medicine study conduct.
